Organon to divest Jada System for up to $465M to Laborie

Organon (OGN) announced that it has entered into an agreement with Laborie Medical Technologies for them to acquire the Jada System. The transaction, valued at up to $465M, is comprised of $440M to be paid at closing, subject to certain closing adjustments, and a potential payment of up to $25M subject to the achievement of certain 2026 revenue targets. Approximately 100 employees are expected to transfer to Laborie as part of the agreement. The total transaction value of up to $465M represents 6.5x Jada’s trailing 12-months revenues, reflective of Jada’s successful launch and U.S. expansion over the past four years. Net proceeds from the transaction will be applied to debt reduction consistent with the company’s previously stated objective of reducing its net debt to adjusted EBITDA ratio. The transaction has been approved by the board of directors of the company and is expected to close in the first quarter of 2026, subject to required regulatory approvals and other customary closing conditions, including the appropriate involvement of employee representatives in certain markets outside of the U.S.